Ichor and Janssen partnership will create chronic hepatitis B immunotherapies
This worldwide license agreement, which Johnson & Johnson Innovation facilitated, obligates both companies to collaborate for this DNA-based vaccine. As part of the agreement, Janssen will be responsible for developmental costs and commercialization costs. Additionally, the company must pay for the manufacturing and distribution of Ichor’s TriGrid Delivery System.
Also as part of the agreement, Ichor will receive a single upfront payment. The company’s development, sales, and research and design support will receive additional payments. All of the payments total approximately $85 million. There will be additional royalty payments for any future sales of the licensed product.
Hepatitis B is a potentially fatal liver infection. Over 2 billion people have hepatitis B virus infections, and there are more than 240 million people with chronic hepatitis B infections. Available treatments do not eliminate the virus completely and have severe side effects and adverse reactions that may further damage the patient’s health.